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ABSTRACT 
Objective: The aim of this pilot study was to determine the combined effect of vitamin D and 
omega-3 PUFA supplementation on airway function and inflammation in recreational athletes 
with exercise-induced bronchoconstriction (EIB). Methods: Ten recreational athletes with 
EIB participated in a single blind, placebo-controlled trial over six consecutive weeks. All 
subjects attended the laboratory on three occasions. Each visit was separated by a period of 3 
weeks; visit 1 (usual diet), visit 2 (placebo) and visit 3 (SMARTFISH® NutriFriend 2000; 
30µg vitamin D3 - 3000mg EPA, 3000mg DHA) consumed once daily for a period of 3-
weeks. Venous blood was collected at the beginning of each trial to determine vitamin D 
status. Spirometry was performed pre and post eucapnic voluntary hyperpnea (EVH). 
Results: The ∆FEV1max post EVH was not different between visits (usual diet: -15.9 ± 
3.6%; placebo: -16.1 ± 6.1%; vitamin D + omega-3 PUFA: -17.8 ± 7.2%). Serum vitamin D 
remained unchanged between visits. Conclusion: Vitamin D and omega-3 PUFA 
supplementation does not attenuate the reduction in lung function post EVH. These findings 
should be viewed as preliminary until the results of randomised controlled trials are made 
available.  
 
 
 
 
 
 
Key words: Airway dysfunction, Exercise-induced bronchoconstriction, Inflammation, 
Omega-3 polyunsaturated fatty acids, Vitamin D. 
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INTRODUCTION  2 
Exercise-induced bronchoconstriction (EIB) describes the phenomenon of acute, transient 3 
airway narrowing in association with physical activity [1] and is highly prevalent in both 4 
recreational and elite level athletes [2,3]. Although the precise pathogenesis of EIB is not 5 
completely understood, it is generally acknowledged that exercise hyperpnea initiates 6 
bronchoconstriction by inducing osmotic changes at the distal airway surface [4]. This 7 
precipitates the release of pro-inflammatory mediators including histamine, neuropeptides, 8 
cytokines, cysteinyl leukotrienes and prostaglandins, ultimately resulting in airway smooth 9 
muscle contraction [5]. In the chronic setting, repeated, prolonged periods of exercise 10 
hyperpnea have been associated with injury-repair cycling of the airway epithelium resulting 11 
in smooth muscle remodelling [6,7]  and the development of EIB in athletes [2].  12 
The mainstay of treatment for EIB consists of pharmacological medication (e.g. short acting 13 
inhaled beta-2 agonists (SABA)) [1]. However, there is accumulating evidence that non-14 
pharmacological interventions, such as dietary modification, may have utility in the treatment 15 
of EIB in athletes [8]. This is pertinent given the possible side effects of chronic beta-2 16 
agonist therapy (e.g. development of tachyphlaxis and degenerative changes in lung function) 17 
[9]. One of the most promising dietary interventions is fish oil supplementation. Specifically, 18 
omega-3 polyunsaturated fatty acids (PUFA) (eicosapentaenoic acid (EPA) and 19 
docosahexaenoic acid (DHA)) have previously been shown to attenuate airway inflammation 20 
and the bronchoconstrictor response to exercise hyperpnea [10,11]. The purported therapeutic 21 
effect of omega-3 PUFA for the treatment of EIB in athletes is biologically plausible; 22 
however the findings to date remain equivocal [10-16]. The proposed mechanism of omega-3 23 
PUFA protecting against EIB consists of EPA and DHA competitively inhibiting arachidonic 24 
acid metabolism and therefore reducing the generation of pro-inflammatory leukotrienes, 25 
prostaglandins and cytokine production from inflammatory cells [17].  26 
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Indeed, other dietary interventions may also be important. Recently, epidemiological studies 27 
have highlighted a direct association between vitamin D deficiency and the incidence and 28 
severity of asthma [18]. Although the evidence is sparse, low serum vitamin D levels have 29 
previously been associated with reduced lung function and increased airways hyper-reactivity 30 
to exercise in asthmatic children with EIB [19]. Mechanisms by which vitamin D may 31 
prevent EIB are likely multifactorial. The vitamin D receptor is expressed in most tissues and 32 
it has been proposed that vitamin D deficiency may result in an increase in mast cells, 33 
histamine release and apoptosis [20,21]. Furthermore, a reduction in the expression of pro-34 
inflammatory interleukins (i.e. interleukin (IL)-13) associated with bronchoconstriction has 35 
been observed [22]. Vitamin D receptors in respiratory epithelial cells and bronchial smooth 36 
muscle have also been reported to regulate the expression of genes implicated in the 37 
pathogenesis of asthma [23] and smooth muscle proliferation (i.e. airway remodelling) [24]. 38 
Consequently, as vitamin D deficiency may play a role in the pathogenesis of lung disease, 39 
supplementation may present a novel preventative and/or therapeutic strategy for athletic 40 
individuals with EIB.  41 
The principal aim of this pilot study was to evaluate the combined effect of a commercially 42 
available vitamin D and omega-3 PUFA supplement (SMARTFISH® NutriFriend 2000), on 43 
airway function in recreational athletes with EIB. We hypothesised that lower levels of 44 
vitamin D would be associated with reduced lung function, and that vitamin D and omega-3 45 
PUFA supplementation would attenuate airway inflammation and bronchoconstriction 46 
following an indirect bronchoprovocation challenge. Eucapnic voluntary hyperpnea (EVH) 47 
was selected as the bronchoprovocation challenge since it is the test currently favoured by the 48 
International Olympic Committee-Medical Commission (IOC-MC) for diagnosing EIB in 49 
elite athletes [25]. 50 
 51 
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METHODS 52 
Preliminary screening 53 
One hundred and one endurance trained recreational athletes (mean ± SD: 6 ± 1 hours 54 
training/week) were recruited and subsequently tested for EIB via a EVH challenge 55 
(described below). Sixteen athletes (17%) were positive for EIB (i.e. ≥10% fall in FEV1 post 56 
EVH) and thus considered eligible for participation.  57 
Study population  58 
Ten athletes (runners, cyclists and triathletes) (male: n = 9) with EIB (63%) agreed to take 59 
part in the study. All subjects were non-smokers, free from respiratory, cardiovascular, 60 
metabolic and psychiatric disease, and any other significant medical condition except mild 61 
asthma. Four subjects had a previous physician-based diagnosis of clinical asthma and were 62 
prescribed a SABA; two of the four were also prescribed maintenance-inhaled corticosteroid. 63 
Experimental design 64 
The study was conducted as a single blind placebo-controlled trial over six consecutive 65 
weeks (June – September, United Kingdom). A randomised double-blind crossover design 66 
was not practical due to the half-life (~15 days) of vitamin D [26] (i.e. approximately 6-67 
month wash-out period) and the effect of seasonal variation on airway calibre in atopic 68 
individuals [27]. All subjects were required to attend the laboratory on three occasions. Each 69 
visit was separated by a period of 3 weeks; visit 1 (usual diet), visit 2 (placebo; matching the 70 
treatment beverage for appearance, taste, quantity and packaging) and visit 3 (treatment; 71 
vitamin D + omega-3 PUFA consisting of a 600 ml fruit and berry flavoured beverage - 72 
SMARTFISH® NutriFriend 2000; 30µg vitamin D3 i.e. cholecalciferol, 3000mg EPA, 73 
3000mg DHA) consumed once daily for a period of 3-weeks. SMARTFISH® provided 74 
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documented evidence (i.e. quality assurance) of the content of both placebo and experimental 75 
beverages.  76 
Subjects arrived at the laboratory 1 h postprandial at a similar (± 1 h) time of day following 77 
their usual diet. At visit 1 an assessment of respiratory health and evaluation of allergy status 78 
was determined via completion of the Allergy Questionnaire for Athletes (AQUA) and 79 
aeroallergen skin prick testing. For all visits, venous blood was collected at the beginning of 80 
each trial to determine serum vitamin D status. Spirometry was performed pre- and post-EVH 81 
provocation. Airway inflammation was determined via fractional exhaled nitric oxide (FENO) 82 
(indirect marker for up-regulation of airway inflammation) pre- and 30 min post-EVH. Urine 83 
samples were obtained pre- and 60 min post-EVH for cysteinyl leukotriene (LTE4) and 84 
prostaglandin (9α, 11β- prostaglandin F2) quantification (markers of airway inflammation and 85 
mast cell activation, respectively). With the exception of AQUA and aeroallergen skin prick 86 
testing, all visits were replicated precisely on subsequent visits (Figure 1).  87 
Subjects were excluded from follow-up assessment if changes in training and/or health status, 88 
respiratory tract infection, allergen or sunlight exposure were reported between visits. 89 
Subjects were asked to abstain from dietary supplements (e.g. vitamins and anti-oxidants) 90 
throughout the duration of the study and SABA and inhaled corticosteroid medication for 24 91 
and 72 h, respectively, prior to each visit. Northumbria University ethics committee approved 92 
all tests and procedures, and all subjects provided written informed consent for 93 
experimentation with human subjects. 94 
Atopic Status 95 
Sensitivity to seven common airborne allergens (early blossom tree, mid blossom tree, grass, 96 
weed, mould, cat and dust mite) were assessed via skin prick testing [28]. A subject was 97 
classified as atopic if, in the skin prick test, at least 1 allergen caused a wheal of at least 3 mm 98 
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in diameter, in the presence of a negative saline control and positive histamine. Subjects also 99 
completed AQUA to assess allergic symptoms [29]. An athlete was considered to be allergic 100 
if they presented with a positive skin prick test and a positive AQUA score ≥5. 101 
Pulmonary function  102 
Spirometry 103 
Lung function was assessed by forced flow-volume spirometry (MicroLoop ML3535; 104 
Cardinal Health, UK) [30].  105 
Eucapnic voluntary hyperpnea 106 
Bronchoprovocation challenge testing with EVH was performed as described previously 107 
[31,32]. In brief, subjects were required to inhale a mixture of dry compressed gas (21% O2, 108 
5% CO2, balance N2) at a ventilation rate equivalent to approximately 85% maximal 109 
voluntary ventilation (MVV)–calculated as 30*FEV1 for a period of 6 min. Subjects viewed 110 
their ventilatory volume in real-time in order to ensure they maintained the target level. A 111 
positive diagnosis for EIB was defined by a post-EVH reduction in FEV1 of ≥10% compared 112 
to resting spirometry.  113 
Airway inflammation  114 
Fraction of exhaled nitric oxide (FENO) was the first test performed during each visit and 115 
measured using a hand-held measuring device (NIOX MINO®) (Aerocrine AB, Stockholm, 116 
Sweden). FENO levels were obtained in accordance with international guidelines [33].  117 
Vitamin D status 118 
The Elecsys Total 25-hydroxyvitamin D assay (Roche Diagnostics GmbH, Germany) was 119 
used for the quantative determination of total serum 25-hydroxyvitamin D (25(OH)D) 120 
(nmol/L) [34]. Intra-assay coefficient of variation was <10%. Vitamin D status was classified 121 
8 
 
according to previous recommendations as sufficient: 75 – 100 nmol/L; insufficient: 50-75 122 
nmol/L; deficient: < 50 nmol/L [19,35].  123 
Urinary inflammatory markers 124 
Enzyme immunoassays of LTE4 and 9α, 11β- prostaglandin F2 were performed in serially 125 
diluted urine (Cayman Chemical Company, Ann Arbor, MI) as previously described [36,37]. 126 
Inter- and intra-assay coefficient of variation was <10%. All data were normalised and 127 
presented as nanograms of excreted mediator per millimole of creatinine. Creatinine analyses 128 
were performed using a modification of Jaffe’s creatinine protocol [38].  129 
Nutrient intake and compliance 130 
Subjects were instructed to maintain their usual diet (maximum of one fish meal per week) 131 
and physical activity levels throughout the duration of the study. Adherence to treatment 132 
regimens was monitored by athletes documenting the time and date of consumption and 133 
returning any supplements that were not consumed. In accordance with comparable research 134 
a compliance of ≥90% was considered acceptable [36]. 135 
Statistical analysis 136 
Normality of data was assessed using a Kolmogorov-Smirnov test and Levene’s test to check 137 
for homogeneity of variance between groups. A two-way repeated measures analysis of 138 
variance (ANOVA) was used to analyse within subject effects. Mauchly’s test was conducted 139 
to determine if sphericity was violated. If sphericity was violated, the repeated measures 140 
ANOVA was corrected using a Greenhouse-Geisser adjustment factor. A Bonferroni post hoc 141 
analysis was employed for multiple comparisons (P<0.05). A one way repeated measures 142 
ANOVA was employed where relevant and relationships between variables were determined 143 
via liner regression analysis (Pearson correlation coefficients). AUC0-20min was calculated by 144 
the trapezoidal method and expressed as percentage fall in FEV1. Data was analysed using 145 
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PASW Statistics 21 statistical software package (SPSS Inc., Version 21, Chicago, IL) and 146 
GraphPad Prism Version 5.0 (GraphPad Software, San Diego, California, USA). Data are 147 
expressed as mean (± SD) and significance was set at P < 0.05. 148 
149 
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RESULTS 150 
Baseline characteristics, allergy and pre-challenge lung function 151 
Ten recreational athletes (male: n = 9) completed the study. Subjects’ characteristics are 152 
presented in Table 1. Eight athletes were atopic to skin prick testing and eight had a positive 153 
(≥5) AQUA questionnaire. Seven athletes with a positive AQUA questionnaire were also 154 
atopic and therefore considered allergic. Five subjects reported respiratory symptoms (e.g. 155 
cough, wheeze, dyspnea etc.) in association with exercise. All pulmonary function measures 156 
were within normal predicted limits with no evidence of airflow obstruction. In addition, no 157 
difference in resting lung function was observed between visits (P>0.05) (Table 2).   158 
Compliance to treatment regimens 159 
Excellent adherence to treatment regimens was reported for placebo and vitamin D + omega-160 
3 PUFA (99.5 ± 1.1% and 98.5 ± 3.4%) diets, respectively (P>0.05).  161 
Airway response to eucapnic voluntary hyperpnea  162 
Similar ventilation rates were achieved between all visits (usual diet: 105 ± 25 L.min-1; 163 
placebo: 101 ± 17 L.min-1; vitamin D + omega-3 PUFA: 100 ± 15 L.min-1) (P = 0.854). All 164 
athletes maintained >60% MVV throughout EVH thus achieving test validation [39]. The 165 
∆FEV1max post-EVH was no different between visits (usual diet: -15.9 ± 3.6%; placebo:-166 
16.1 ± 6.1%; vitamin D + omega-3 PUFA: -17.8 ± 7.2%) (P = 0.719). No difference was 167 
observed in the reduction in FEV1 between conditions at any time point (P>0.05) (Figure 2) 168 
(Table 3). Furthermore, no difference was observed for AUC0-20 min % fall in FEV1 between 169 
visits (usual diet: 198.0 ± 75.9%; placebo: 239.7 ± 99.4%; vitamin D + omega-3 PUFA: 170 
256.9 ± 135.5%) (P = 0.455).  171 
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Vitamin D status  172 
At visit one (usual diet), three athletes (30%) had sufficient levels of vitamin D, five were 173 
insufficient, and two were deficient. At visit two (placebo), two athletes were sufficient, six 174 
were insufficient and two were deficient. At visit three (vitamin D + omega-3 PUFA), three 175 
were sufficient, six were insufficient and one was deficient. No difference in serum vitamin D 176 
was observed between visits (usual diet: 64.2 ± 17.4 nmol.L-1; placebo: 65.1 ± 16.5 nmol.L-1; 177 
vitamin D + omega-3 PUFA: 69.0 ± 16.9 nmol.L-1 (P = 0.798). In addition, change in serum 178 
vitamin D status between visits did not correlate with ∆FEV1max (r = 0.11; P = 0.559).  179 
Airway inflammation  180 
No difference in FENO was observed pre-EVH between visits (usual diet: 28 ± 16ppb; 181 
placebo: 31 ± 23ppb; vitamin D + omega-3 PUFA: 37 ± 27ppb) (P = 0.182) or post-EVH 182 
between visits (usual diet: 27 ± 19ppb; placebo: 25 ± 19ppb; vitamin D + omega-3 PUFA: 28 183 
± 18ppb) (P = 0.834). However, a reduction in FENO post-EVH was observed within 184 
condition for placebo (-20.1%) and vitamin D + omega-3 PUFA (-28.9%), respectively 185 
(P<0.05) (Figure 3). 186 
Urinary inflammatory markers 187 
Cysteinyl leukotriene LTE4 188 
LTE4 was higher pre-EVH following vitamin D + omega-3 PUFA: 104.1 ± 26.7 ng/mmol 189 
creatinine compared to both usual diet: 72.6 ± 16.6 ng/mmol creatinine and placebo: 72.6 ± 190 
22.9 ng/mmol creatinine (P<0.05). No difference was observed between usual diet and 191 
placebo (P>0.05). LTE4 was higher post-EVH following vitamin D + omega-3 PUFA: 99.1 ± 192 
29.2 ng/mmol creatinine compared to placebo: 61.0 ± 13.7 ng/mmol creatinine (P = 0.007). 193 
No difference was observed between usual diet and placebo or usual diet and vitamin D + 194 
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omega-3 PUFA respectively (P>0.05) (Figure 4). LTE4 did not correlate with ∆FEV1max (r = 195 
0.30; P = 0.107).  196 
9α, 11β- prostaglandin F2 197 
No difference in 9α, 11β- prostaglandin F2 was observed pre-EVH between visits (usual diet: 198 
88.9 ± 59.1 ng/mmol creatinine; placebo: 82.8 ± 37.6 ng/mmol creatinine; vitamin D + 199 
omega-3 PUFA: 79.2 ± 43.7 ng/mmol creatinine) or post-EVH between visits (usual diet: 200 
(usual diet: 104.0 ± 41.7 ng/mmol creatinine; placebo: 101.1 ± 56.8 ng/mmol creatinine; 201 
vitamin D + omega-3 PUFA: 90.3 ± 48.0 ng/mmol creatinine) (P>0.05) (Figure 4). A 202 
correlation was observed between 9α, 11β- prostaglandin F2 post-EVH and ∆FEV1max (r = 203 
0.45; P = 0.017).  204 
205 
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DISCUSSION  206 
This study has shown, contrary to our hypothesis, that the combination of vitamin D and 207 
omega-3 PUFA supplementation over a 3-week period does not reduce markers of airway 208 
inflammation or attenuate the reduction in lung function post EVH in recreational athletes 209 
with EIB. Furthermore, serum vitamin D status does not appear to correspond directly to the 210 
severity of bronchoconstriction following indirect bronchoprovocation. The study design and 211 
intervention of the present study was based on the premise that dietary modification with a 212 
commercially available self-administrated supplement would be pragmatic and overall 213 
applicable to ‘real-life’.  214 
Vitamin D deficiency (serum 25-hydroxyvitamin D <50 nmol.L-1) has previously been 215 
associated with a reduction in lung function and increased reactivity to exercise in asthmatic 216 
children with EIB [19]. However, the precise role of vitamin D in the pathogenesis of EIB 217 
has yet to be determined. In the current study 20% (2/10) of athletes presented with vitamin 218 
D deficiency following their usual diet. This is in contrast to previous findings where 51% 219 
(23/45) of asthmatic children with EIB were vitamin D deficient [19]. The dissociation 220 
between studies is somewhat surprising, however supports the notion that physical activity is 221 
directly related to the level of sun light exposure [40]. However, it is important to 222 
acknowledge that the comparison of prevalence estimates of vitamin D deficiency between 223 
studies may be confounded by the population studied (i.e. adults versus children). In addition, 224 
as the current study was conducted in the summer months (June – September, United 225 
Kingdom), this may, in part, explain the limited number of athletes presenting with vitamin D 226 
deficiency. However, it must be acknowledged that the long half-life of vitamin D [26] 227 
combined with controlling environmental factors (e.g. sunlight exposure and diet) limits the 228 
standardisation of vitamin D trials in vivo (i.e. human studies). Nevertheless, further work is 229 
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required to fully determine the extent of vitamin D deficiency and thus requirement of 230 
supplementation in athletic individuals. 231 
In the present study adherence to the treatment regimens was high, however no difference 232 
was observed in serum vitamin D following supplementation. Previous epidemiological 233 
studies have highlighted a positive correlation between lung function and serum vitamin D 234 
levels [19,41], whereas others have shown no association [42]. However, observational 235 
studies do not confirm causality. Our findings show a poor relationship between vitamin D 236 
status and severity of bronchoconstriction, thus disputing a direct association.  These findings 237 
are supported by a recent comparable study demonstrating no effect of vitamin D 238 
supplementation in children with mild asthma [43]. However, a general consensus regarding 239 
the optimal vitamin D dose has yet to be established (see recent review by Owens et al. [44]). 240 
It is therefore reasonable to speculate that the dose employed within the current study (30 241 
µg/day) or indeed length of supplementation was not sufficient to elicit a therapeutic effect. 242 
Thus, the optimal level of vitamin D supplementation remains elusive and clinical trials are 243 
required before informed recommendations can be employed.  244 
Mickleborough et al. [10,11] previously reported that omega-3 PUFA (3.2g/day EPA and 245 
2.2g/day DHA) derived from fish oil results in a reduction in markers of airway inflammation 246 
(e.g. LTE4 and 9α, 11β- prostaglandin F2) and an attenuated bronchoconstrictor response 247 
following exercise in EIB and asthmatic patients, respectively. More recently, similar 248 
findings have been reported by the same group following EVH bronchoprovocation [12,36]. 249 
Although Arms et al. [16] also observed a 50% inhibition of total leukotriene count in 250 
peripheral blood in mild asthmatics following 10 weeks of daily fish oil supplementation 251 
(3.2g EPA and 2.2g DHA), in agreement with our findings no change was observed in 252 
∆FEV1max post indirect bronchoprovocation.  In further support of this concept, Brannan et 253 
al. [15] recently found that a 3-week period of omega-3 supplementation (4.0g/day EPA and 254 
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2.0g/day DHA) does not improve bronchial hyper-responsiveness to mannitol or inhibit 255 
urinary excretion of mast cell mediators in adults with mild-moderate asthma.  256 
This observation is comparable with findings from the present study where no difference was 257 
observed in urinary 9α, 11β- prostaglandin F2 between visits. Although urinary LTE4 258 
increased pre and post EVH following vitamin D + omega-3 PUFA, the majority of athletes 259 
within our cohort were atopic (80%) and allergic (70%), and thus any potential anti-260 
inflammatory effect of vitamin D and omega-3 PUFA may have been counteracted by the 261 
variation in allergen exposure (e.g. pollen count, house dust mite etc.) between visits [27]. In 262 
keeping with our findings however, Moreira et al. [45] observed no difference in FENO 263 
following short-term dietary supplementation with omega-3 PUFA in woman with stable 264 
asthma.  265 
Our finding of a correlation between ∆FEV1max and urinary excretion of 9α, 11β- 266 
prostaglandin F2 (P<0.05) further supports the role of mast cells in EIB [37]. Although the 267 
urine sampling time-points post challenge were not identical, similar to Kippelen et al. [37] 268 
no association existed between ∆FEV1max and urinary excretion of LTE4.  This observation 269 
could suggest that 9α, 11β- prostaglandin F2 is a more sensitive marker of EIB in atopic 270 
individuals than LTE4, which warrants further investigation.  271 
Although Mickleborough and Rundell [17] have highlighted statistical limitations to explain 272 
the inconsistency in results between studies [17], the majority of trials have consisted of a 273 
comparable sample size to the present study [10,11,16]. However, it should be acknowledged 274 
that the diagnostic methodology used to quantify the extent of bronchoconstriction often 275 
varies between studies [10-12,15]. Furthermore, it has previously been shown that a poor 276 
relationship exists between indirect bronchoprovocation challenges (i.e. exercise and EVH) 277 
[46,47]. It is therefore possible that the purported therapeutic effect of treatment varies 278 
according to the specific bronchoprovocation challenge employed.  279 
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Nonetheless, the disparities in findings are still somewhat surprising given the similarities in 280 
study design, population, sample size and similar dose of the respective interventions 281 
[10,11,16]. Whilst the form of vitamin D and omega-3 PUFA administration in the present 282 
study differed from previous research, there is currently no consensus in the literature to 283 
suggest that the absorption or indeed effect of supplementation significantly varies according 284 
to the form of consumption (i.e. encapsulated supplement versus commercially available 285 
nutritional beverage). However, it should be acknowledged that in contrast to previous work 286 
[6,10,14,19,40,41] equal quantities of EPA and DHA (3.0g/day) were employed in the 287 
current study. It is therefore possible that EPA may be more important than DHA in 288 
attenuating EIB. This theory is consistent with a previous pilot study by Head et al. [13] 289 
where supplementation with 4.0g/day of DHA did not attenuate bronchoconstriction or 290 
airway inflammation in asthmatic patients following EVH. Moreover, a recent mouse model 291 
of asthma observed pro-inflammatory effects following the consumption of DHA over a six 292 
week period [48].  293 
Overall however, the results of the present study support the current recommendation by the 294 
American Thoracic Society that the evidence is not currently strong enough to confirm that 295 
omega-3 PUFA’s are effective in the large majority of patients with EIB [1]. 296 
Pertinent to the present study and previous research [10-12,16,36], poor short-term test re-test 297 
clinical reproducibility of indirect bronchoprovocation (i.e. exercise and EVH) [49,50] has 298 
recently been observed in patients with mild EIB. Therefore, although the combination of 299 
vitamin D and omega-3 PUFA does not appear to attenuate the ∆FEV1max post 300 
bronchoprovocation, the inherent variability of a test employed to determine changes in lung 301 
function should be considered when advocating the efficacy of a treatment intervention to 302 
avoid masking or overestimating the proposed therapeutic benefit. Likewise, the use of FENO 303 
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as a marker of airway inflammation may be confounded given the high ventilatory demand of 304 
EVH (i.e. exhaled nitric oxide often falls from baseline values even when EIB is confirmed).  305 
Methodological considerations / future research  306 
Although this study is the first interventional trial to address the impact of combining vitamin 307 
D and omega-3 PUFA supplementation in athletic individuals with EIB, there are a number 308 
of important considerations. Firstly, given the small sample size of the cohort, the results 309 
should be viewed with some caution. Whilst we are confident that false negative results (i.e. 310 
type II error) have not been reported, further work with a larger sample size is still required to 311 
provide a definitive answer. Secondly, the optimal level of vitamin D supplementation 312 
remains elusive and clinical trials are required before informed recommendations can be 313 
employed. Once established, randomised controlled trials are required to determine the 314 
individual and combined efficacy of vitamin D and omega-3 PUFA for the treatment of EIB 315 
in athletes. Whilst highly speculative, the possibility exists that the lipophilic properties of 316 
vitamin D may compete with omega-3 PUFA by an unknown mechanism. Thirdly, to 317 
understand the mechanism of action of specific interventions, future studies should assess 318 
nutritional deficiencies (i.e. vitamin D and omega-3 PUFA status) prior to study entry and 319 
recruit homogenous cohorts of athletes according to severity of disease and specific clinical 320 
phenotypes (e.g. asthma, EIB, airway hyper-responsiveness, atopy etc.) rather than ‘pooling’ 321 
heterogeneous cohorts. Finally, the longitudinal impact of vitamin D and/or omega-3 PUFA 322 
supplementation has yet to be established. Conducting randomised double-blind crossover 323 
design studies (acknowledging the limitations of vitamin D washout) may provide value in 324 
this setting.    325 
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Conclusion 326 
In conclusion, this pilot study has shown that a 3-week period of vitamin D and omega-3 327 
PUFA supplementation does not reduce markers of airway inflammation nor attenuate the 328 
reduction in lung function post EVH. In addition, vitamin D status does not appear to 329 
correspond directly to the severity of bronchoconstriction in recreational athletes with EIB. 330 
However, these findings should be viewed as preliminary until the results of randomised 331 
controlled trials are made available.  332 
333 
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KEY ISSUES 334 
 Vitamin D deficiency has previously been associated with the development and 335 
severity of asthma, with low serum vitamin D levels associated with reduced lung 336 
function and increased reactivity to exercise in children with EIB.  337 
 338 
 Omega-3 PUFA supplementation has been shown to attenuate airway inflammation 339 
and bronchoconstriction following indirect bronchoprovocation.   340 
 341 
 The aim of this pilot study was to determine the combined effect of acute vitamin D 342 
and omega-3 PUFA supplementation on airway function in recreational athletes with 343 
EIB.  344 
 345 
 The combination of vitamin D and omega-3 PUFA supplementation does not reduce 346 
markers of airway inflammation nor attenuate the reduction in lung function 347 
following EVH.  348 
 349 
 Serum vitamin D status does not appear to directly correspond to the severity of 350 
bronchoconstriction.  351 
 352 
 The inherent variability of a test (i.e. indirect bronchoprovocation) employed to 353 
determine changes in lung function should be considered when advocating the 354 
efficacy of a treatment intervention to avoid masking or overestimating the proposed 355 
therapeutic benefit.  356 
 357 
 Further work is required to determine the individual and combined effect of omega-3 358 
PUFA and vitamin D as a non-pharmacological treatment for EIB. The findings of the 359 
present study should be viewed as preliminary until the results of randomised 360 
controlled trials are made available.  361 
 362 
 363 
364 
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TABLE HEADINGS 365 
Table 1: Subject clinical characteristics.  366 
 367 
Definitions of abbreviations: BMI, body mass index.  368 
  369 
Table 2: Baseline pulmonary function.  370 
 371 
Definitions of abbreviations: FEV1, forced expiratory volume in 1-s; FVC, forced vital 372 
capacity; PEF, peak ﬂow rate. 373 
 374 
Table 3: Baseline lung function and response to eucapnic voluntary hyperpnea.  375 
Definitions of abbreviations: FEV1, forced expiratory volume in 1-s 376 
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Table 1. 377 
Subject 
Sex 
(M:F) 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
BMI 
(kgm-2) 
Training 
(hrswk-1) 
Physician 
diagnosed asthma Medication 
Self-report 
symptoms Allergy 
1 M 42 177.7 90.3 28.6 6 No Nil Asymptomatic No 
2 M 27 185.6 87.4 25.4 6 No Nil Asymptomatic No 
3 M 36 178.5 72.5 22.8 6 No Nil Asymptomatic Yes 
4 M 28 181.3 79.4 24.2 6 No Nil Asymptomatic Yes 
5 M 48 173.7 75.6 25.1 6 No Nil Asymptomatic Yes 
6 M 28 177.0 78.8 25.2 6 Yes SABA + ICS Symptomatic Yes 
7 F 42 166.6 64.2 23.1 6 Yes SABA Symptomatic No 
8 M 39 177.9 88.7 28.0 6 Yes SABA + ICS Symptomatic Yes 
9 M 34 181.1 72.7 22.2 6 Yes SABA + ICS Symptomatic Yes 
10 M 24 183.3 84.5 25.1 4.5 No Nil Symptomatic Yes 
Total 9:1 35 ± 8 178.3 ± 5.5 79.4 ± 8.4 25.0 ± 2.1 6 ± 1 4/10 4/10 5/10 7/10 
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Table 2. 378 
Data presented as Mean ± SD. n =10.  379 
Baseline pulmonary function 
 Visit 1 
Usual diet 
Visit 2 
Placebo 
Visit 3 
Vitamin D + Omega-3 
FEV1 (L) 4.04 ± 0.85 4.12 ± 0.77 4.00 ± 0.80 
FEV1 (% predicted) 96.5 ± 15.4 98.4 ± 12.0 95.4 ± 12.2 
FVC (L) 5.61 ± 0.81 5.69 ± 0.78 5.61 ± 0.86 
FVC (% predicted) 111.6 ± 10.7 113.1 ± 9.5 111.2 ± 10.4 
FEV1/FVC (%) 71.4 ± 5.4 71.9 ± 4.2 71.0 ± 4.7 
PEF (L/min) 552.4 ± 103.3 569.5 ± 85.6 556.1 ± 107.5 
PEF (% predicted) 97.7 ± 13.7 100.6 ± 7.9 97.9 ± 11.5 
23 
 
Table 3. 380 
 
Baseline ∆FEV1max 
Subject Visit 1: FEV1 (% predicted) Visit 1: Usual diet Visit 2: Placebo Visit 3: Vitamin D + Omega-3 PUFA 
1 87.0 -19.6 -12.5 -17.5 
2 104.9 -17.2 -20.8 -20.5 
3 102.6 -11.5 -20.1 -16.5 
4 95.2 -12.9 -13.2 -14.7 
5 89.8 -12.1 -12.1 -7.5 
6 130.0 -13.6 -9.0 -12.0 
7 80.2 -14.4 -17.6 -14.7 
8 95.8 -16.8 -9.4 -25.1 
9 104.4 -18.2 -16.9 -16.1 
10 75.4 -22.6 -28.9 -33.4 
Mean ± SD 96.5 ± 15.4 -15.9 ± 3.6 -16.1 ± 6.1 -17.8 ± 7.2 
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FIGURE LEGENDS 381 
Figure 1. Schematic depicting the experimental design.  382 
Definitions of abbreviations: AQUA, The Allergy Questionnaire for Athletes; EIB, 383 
exercise-induced bronchoconstriction; FEV1, forced expiratory volume in 1-s; EVH; 384 
Eucapnic voluntary hyperpnea; FENO, fractional exhaled nitric oxide.  385 
 386 
Figure 2. Percentage change in FEV1 post EVH between visits. Usual diet (open circles); 387 
placebo (closed circles); vitamin D + omega-3 PUFA (closed triangles). Broken horizontal 388 
line represents abnormal lung function (i.e. ≥10% fall in FEV1). Placebo SD error lines 389 
omitted to improve clarity of graph.  390 
 391 
Figure 3. Fractional exhaled nitric oxide (FENO) concentration (ppb) pre-EVH (closed bar) 392 
and 30 min post-EVH (open bar) between visits. * denotes significant difference within 393 
condition between pre- and post-EVH (P<0.05) 394 
 395 
Figure 4. Panel a). Urinary LTE4 concentration pre EVH (closed bar) and 60 min post EVH 396 
(open bar) between visits. Panel b). Urinary 9α, 11β- prostaglandin F2 pre EVH (closed bar) 397 
and 60 min post EVH (open bar) between visits. * denotes significant difference pre-EVH 398 
between condition (P<0.05). # denotes significant difference post-EVH between condition 399 
(P<0.05). 400 
 401 
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 410 
 411 
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